UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

From laboratory to Phase I/II cancer trials with recombinant biotherapeutics

European journal of cancer (1990), 2007-11, Vol.43 (17), p.2515-2522

2007

Volltextzugriff (PDF)

Immunohistochemical Expression of Vascular Endothelial Growth Factor and Microvessel Counting as Prognostic Indicators in Node-Negative Colorectal Cancer

Tumor biology, 2005-01, Vol.26 (1), p.1-8

2005

Volltextzugriff (PDF)

Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT)

European journal of nuclear medicine and molecular imaging, 2004-08, Vol.31 (8), p.1090-1096

2004

Volltextzugriff (PDF)

EMA/CO for High-Risk Gestational Trophoblastic Tumors Results From a Cohort of 272 Patients

Journal of clinical oncology, 1997-09, Vol.15 (9), p.3168-3168

1997

Volltextzugriff (PDF)

Clinical evidence of efficient tumor targetting based on single-chain Fv antibody selected from a combinatorial library

Nature medicine, 1996-09, Vol.2 (9), p.979-984

1996

Volltextzugriff (PDF)

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy

Annals of oncology, 1997-05, Vol.8 (5), p.477-483

1997

Volltextzugriff (PDF)

Phage libraries for generation of clinically useful antibodies

The Lancet (British edition), 1994-02, Vol.343 (8895), p.455-456

1994

Volltextzugriff (PDF)

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

The Lancet (British edition), 1991-08, Vol.338 (8765), p.487-490

1991

Volltextzugriff (PDF)

Secondary tumours following etoposide containing therapy for germ cell cancer

Annals of oncology, 1995-01, Vol.6 (1), p.35-40

1995

Volltextzugriff (PDF)

Taking engineered anti-CEA antibodies to the clinic

Journal of immunological methods, 1999-12, Vol.231 (1), p.261-273

1999

Volltextzugriff (PDF)

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

Journal of immunological methods, 1995, Vol.179 (1), p.105-116

1995

Volltextzugriff (PDF)

First clinical experience with ADEPT

Advanced drug delivery reviews, 1996-12, Vol.22 (3), p.365-367

1996

Volltextzugriff (PDF)

The management of high-risk gestational trophoblastic tumours (GTT)

International journal of gynecology and obstetrics, 1998-04, Vol.60 (S1), p.S65-S70

1998

Volltextzugriff (PDF)

CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells

European journal of cancer (1990), 1993, Vol.29 (14), p.1995-2002

1993

Volltextzugriff (PDF)

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody

European journal of cancer (1990), 1998-06, Vol.34 (7), p.968-976

1998

Volltextzugriff (PDF)

Biodistribution studies

Advanced drug delivery reviews, 1996-12, Vol.22 (3), p.325-329

1996

Volltextzugriff (PDF)

1169 Placental site trophoblastic tumours at charing cross 1975–1995

European journal of cancer (1990), 1995-11, Vol.31, p.S244-S244

1995

Volltextzugriff (PDF)

Phase I study of radioimmunoguided surgery (RIGS) with anti-CEA single chain Fv antibody in colorectal cancer

European journal of cancer (1990), 1997-09, Vol.33, p.S162-S162

1997

Volltextzugriff (PDF)

Challenges of ultra large scale integration of biomedical computing systems

18th IEEE Symposium on Computer-Based Medical Systems (CBMS'05), 2005, p.64-69

2005

Volltextzugriff (PDF)

Pellagra secondary to 5‐fluorouracil

British journal of dermatology (1951), 1993-05, Vol.128 (5), p.578-580

1993

Volltextzugriff (PDF)

331 Antibody targeting of small cell lung cancer using an anti-CEA antibody

Lung cancer (Amsterdam, Netherlands), 1997-08, Vol.18, p.85-85

1997

Volltextzugriff (PDF)

The importance of measuring quality of life in phase I/II trials of cancer therapy - the effects of antibody targeted therapy: part I

European journal of cancer care, 1997-12, Vol.6 (4), p.267-272

1997

Volltextzugriff (PDF)

FURTHER ADVANCES IN THE MANAGEMENT OF MALIGNANT TERATOMAS OF THE TESTIS AND OTHER SITES

The Lancet (British edition), 1983-04, Vol.321 (8331), p.948-951

1983

Volltextzugriff (PDF)

Antibody targeted therapy in cancer: comparison of murine and clinical studies

Cancer treatment reviews, 1990-09, Vol.17 (2), p.373-378

1990

Volltextzugriff (PDF)

Cancer research campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials

European journal of cancer (1990), 1993, Vol.29 (13), p.1907-1910

1993

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Biological And Medical Sciences
(13)
Adult
(12)
Male
(11)
Medical Sciences
(11)
Oncology
(10)
Chemotherapy
(9)
Middle Aged
(9)
Female
(8)
Pharmacology. Drug Treatments
(8)
Aged
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Tumors
(7)
Adolescent
(6)
Animals
(6)
Antineoplastic Agents
(5)
Cancer
(5)
Dactinomycin - Administration & Dosage
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

From laboratory to Phase I/II cancer trials with recombinant biotherapeutics

Immunohistochemical Expression of Vascular Endothelial Growth Factor and Microvessel Counting as Prognostic Indicators in Node-Negative Colorectal Cancer

Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT)

EMA/CO for High-Risk Gestational Trophoblastic Tumors Results From a Cohort of 272 Patients

Clinical evidence of efficient tumor targetting based on single-chain Fv antibody selected from a combinatorial library

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy

Phage libraries for generation of clinically useful antibodies

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy

Secondary tumours following etoposide containing therapy for germ cell cancer

Taking engineered anti-CEA antibodies to the clinic

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

First clinical experience with ADEPT

The management of high-risk gestational trophoblastic tumours (GTT)

CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody

Biodistribution studies

1169 Placental site trophoblastic tumours at charing cross 1975–1995

Phase I study of radioimmunoguided surgery (RIGS) with anti-CEA single chain Fv antibody in colorectal cancer

Challenges of ultra large scale integration of biomedical computing systems

Pellagra secondary to 5‐fluorouracil

331 Antibody targeting of small cell lung cancer using an anti-CEA antibody

The importance of measuring quality of life in phase I/II trials of cancer therapy - the effects of antibody targeted therapy: part I

FURTHER ADVANCES IN THE MANAGEMENT OF MALIGNANT TERATOMAS OF THE TESTIS AND OTHER SITES

Antibody targeted therapy in cancer: comparison of murine and clinical studies

Cancer research campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials

Suchergebnisse filtern